Back

Efficacy and safety of pemafibrate versus bezafibrate in coronary artery disease patients receiving statin treatment: a randomized, open-label, cross-over study

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Current issues in lipid-lowering therapy Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Akihiro Nakamura

Iwate Prefectural Central Hospital, Morioka (Japan)

5 More presentations in this session

Presentation thumbnail
LDL levels and long-term all-cause mortality in patients from nationwide LIPIDOGRAM 2004-2015 cohort studies.
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Preliminary results from REALITY: a nation-wide study of a database with 1.8 million real-life patients to study atherosclerotic cardiovascular disease and familial hypercholesterolemia in Spain
Professor V. Barrios (Madrid, ES)
Abstract Slides
Presentation thumbnail
Statin therapy in children with familial hypercholesterolemia: A meta-analysis.
Doctor J. Lewek (Lodz, PL)
Abstract Slides
Presentation thumbnail
Low-density lipoprotein cholesterol target attainment among statin-naive Chinese atherosclerotic vascular disease patients
Ms H. Sun (Shatin, HK)
Abstract Slides
Presentation thumbnail
High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry
Doctor M. Sibartie (Uxbridge, GB)
Abstract Slides

Access the full session

Session thumbnail
Current issues in lipid-lowering therapy

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
What’s new in LDL lowering?
thumbnail
Congress Presentation
Stepwise approach to lipid-lowering therapies: which one, when, and for whom?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources